|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Finally, by multiple correspondence analysis of the morphological profiles, we found that all but four of the cases could be grouped in three morphological clusters with some features similar to those of the classic BCR-ABL1-negative myeloproliferative neoplasms.
|
27739437 |
2017 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
|
28551329 |
2017 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET).
|
29134817 |
2017 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
In summary, most patients with chronic eosinophilic leukemia, not otherwise specified and a proportion of those with idiopathic hypereosinophilic syndrome show abnormal bone marrow features similar to the ones encountered in patients with myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm or <i>BCR-ABL1</i>-negative myeloproliferative neoplasm.
|
28495918 |
2017 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Controversies still exist regarding definition of the thrombotic risks in Ph- (BCR/ABL1-) myeloproliferative disorders with thrombocythemia (MPD-T).
|
25807961 |
2016 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.
|
26935241 |
2016 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Molecular routine diagnostics for BCR-ABL1-negative myeloproliferative neoplasms (MPN) currently focusses on mutations in JAK2, CALR and MPL.
|
27447873 |
2016 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
|
26933174 |
2016 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative neoplasms associated with somatic hematopoietic stem cell mutations leading to over activation of JAK-STAT signaling.
|
27017614 |
2016 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
|
27134074 |
2016 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The Janus kinase (JAK)2 p.V617F gain-of-function mutation is a hallmark of BCR-ABL1-negative myeloproliferative neoplasms (MPNs).
|
26361084 |
2016 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.
|
27161873 |
2016 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
There is no systematic screening of myeloproliferative neoplasms; however, the number of ETV6-ABL1-positive cases and the relative incidence of acute lymphoblastic leukemia and myeloproliferative neoplasms suggest that in adulthood ETV6-ABL1 is more common in BCR-ABL1-negative chronic myeloid leukemia-like myeloproliferations than in acute lymphoblastic leukemia.
|
27229714 |
2016 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
|
25840747 |
2015 |
|
Myeloproliferative disease
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of Philadelphia chromosome (Ph) leading to expression of a BCR-ABL1 fusion oncogene.
|
24629639 |
2015 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The BCR-ABL1-negative myeloproliferative neoplasms (MPN) share an increased risk of thrombotic and hemorrhagic complications.
|
26440973 |
2015 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To evaluate the mutation frequency of JAK2 V617F, JAK2 exon 12, MPL exon 10, and CALR exon 9 and the value of the combined tests in the diagnosis of BCR-ABL1-negative myeloproliferative neoplasms (MPNs).
|
26071474 |
2015 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of BCR-ABL1 - an aberrant tyrosine kinase - in the leukaemic blasts.
|
26439403 |
2015 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
RARS-T is a provisional entity in the MDS/MPN (myeloproliferative neoplasm) overlap syndromes, with diagnostic features of RARS, along with a platelet count ≥450 × 10(9)/L and large atypical megakaryocytes similar to those observed in BCR-ABL1 negative MPN.
|
25899435 |
2015 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are approximately 95%, 0%, and 0% in PV, 60%, 20%, and 3% in ET, and 60%, 25%, and 7% in PMF.
|
26182311 |
2015 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To assess the presence of genetic imbalances in patients with myeloproliferative neoplasms (MPNs), 38 patients with chronic eosinophilia were studied by array comparative genomic hybridization (aCGH): seven had chronic myelogenous leukaemia (CML), BCR-ABL1 positive, nine patients had myeloproliferative neoplasia Ph- (MPN-Ph-), three had a myeloid neoplasm associated with a PDGFRA rearrangement, and the remaining two cases were Lymphoproliferative T neoplasms associated with eosinophilia.
|
24813417 |
2014 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm.
|
24927924 |
2014 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The discovery of the JAK2V617F mutation followed by the discovery of other genetic abnormalities allowed important progress in the understanding of the pathogenesis and management of myeloproliferative neoplasms (MPN)s. Classical Breakpoint cluster region-Abelson (BCR-ABL)-negative neoplasms include 3 main disorders: essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF).
|
25486952 |
2014 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Dkk3 is expressed in platelets and megakaryocytes from healthy controls and patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN).
|
24309205 |
2014 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Polycythaemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (MF), are the most common myeloproliferative neoplasms (MPN) in patients without the BCR-ABL1 gene rearrangement.
|
23986553 |
2014 |